The research team used three different approaches to investigate the roles of sEH in obesity-induced colonic inflammation
Researchers have identified a new molecular mechanism to explain the link between obesity and increased risk of colon inflammation, which is a major risk factor in colorectal cancer. The research team, which includes scientists at the University of California Davis, suggest for the first time that inhibiting an enzyme known as soluble epoxide hydrolase, sHE, may abolish this risk of obesity-induced colonic inflammation, say Zhang and colleagues. They note that a few sEH inhibitors, known to be a factor in other inflammatory diseases but not colon cancer before, are now in human clinical trials.
The study was led by doctoral candidates, Wiecang Wang and Jianan Zhang, with their advisor Guodong Zhang in the department of food science at the University of Massachusetts Amherst. The outcomes were outlined in the paper, 'Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation', published in PNAS - Proceedings of the National Academy of Sciences of the United States of America (the official scientific journal of the National Academy of Sciences).
More than one-third, or 34.9 percent, of adults in the US are obese, and obese individuals have a 30-60 percent higher risk of developing colorectal cancer, the third most common and the second leading cause of cancer-related death in the nation. Colon inflammation is an early warning sign of this cancer, and the new research shows why and how obesity increases risk.
In this study, the investigators used a liquid chromatography tandem mass spectrometry (LC-MS/MS)-based metabolomics approach to analyse the profiles of signalling lipids in the colon of groups of lean and obese mice. This allowed them to identify new bioactive lipids which are deregulated in the colon tissues of obese mice.
"Metabolomics is a very powerful tool to find new biomarkers and pathways of human diseases," said Wang. "We found that the concentrations of sEH-produced metabolic products are higher in colons of obese mice. This leads to our discovery that sEH is over-expressed in the colons of obese mice and it is involved in obesity-induced colonic inflammation."
To validate their findings, the research team used three different approaches to investigate the roles of sEH in obesity-induced colonic inflammation. These included using two different sEH inhibitors in experiments as well as a knockout mouse genetically modified not to produce sEH. Results were similar in all cases, reports co-first author Jianan Zhang, no relation to her professor.
"Blocking the enzyme prevents the mouse from developing colonic inflammation. Even in the mice on a high-fat diet, by inhibiting sEH you can completely block colon inflammation," added Wang.
To explore further, the researchers conducted another study in both lean and obese mice who had experimentally-induced colon inflammation. They used molecular analyses to follow a pathway called Wnt because about 90 percent of sporadic colorectal cancers have activating mutations within the Wnt pathway, the professor notes. They found that obesity increases activation of Wnt signalling in the colon, but it too can be eliminated by the two different inhibitors and the knockout.
"In our mouse studies, obesity-induced colon inflammation can be eliminated by inhibiting sEH. So we discovered a new therapeutic target for a very important disease,” said Zhang. "We hope it will be a promising treatment in humans, but mice and humans are very different."
He added that sEH inhibitors are already being explored as a treatment for other diseases such as pain and hypertension, he notes, medical researchers using it would not need to reinvent a whole new approach. "We hope it will be a promising treatment in humans, but mice and humans are very different," Zhang cautions.